Twice yearly inclisiran safe and efficacious in heterozygous familial hypercholesterolaemia

Twice yearly injections of the PCSK9 inhibitor reduced LDL cholesterol, apolipoprotein B and triglycerides.
Twice yearly injections of the PCSK9 inhibitor reduced LDL cholesterol, apolipoprotein B and triglycerides.